Back to Search
Start Over
Combination Olaparib and Temozolomide for the Treatment of Glioma: A Retrospective Case Series.
- Source :
-
Neurology [Neurology] 2022 Oct 24; Vol. 99 (17), pp. 750-755. Date of Electronic Publication: 2022 Oct 24. - Publication Year :
- 2022
-
Abstract
- Background and Objectives: To report the tolerability and efficacy of olaparib with temozolomide (TMZ) for glioma.<br />Methods: Single-center retrospective series of patients with glioma treated with olaparib/TMZ from September 2018 to December 2021.<br />Results: Twenty patients (median age: 42 years, median Karnofsky Performance Status: 90) received olaparib/TMZ for diagnoses of IDH -mutant oligodendroglioma (n = 5), IDH- mutant astrocytoma grade 2-3 (n = 4), IDH -mutant astrocytoma grade 4 (n = 7), or IDH- wildtype glioma (n = 4). One patient was treated upfront and 19 at recurrence (median = 3). Olaparib 150 mg was administered 3 times/week concurrent with TMZ 50-75 mg/m <superscript>2</superscript> daily. Fatigue, gastrointestinal symptoms, and hematologic toxicity were common. Six of 20 patients required dose reduction (n = 4) or discontinuation (n = 2) due to toxicity. Radiographic response was evaluable in 16 and observed (complete + partial) in 4/8 with IDH -mutant grade 2-3 glioma. No responses were seen in patients with grade 4 IDH -mutant astrocytomas (0/5) or IDH -wildtype gliomas (0/3). Progression-free survival was 7.8, 1.3, and 2.0 months, respectively.<br />Discussion: Olaparib/TMZ resulted in objective radiographic response in 50% of evaluable patients with recurrent IDH -mutant grade 2-3 gliomas with encouraging progression-free survival and manageable toxicity. This supports a prospective trial of olaparib/TMZ for this population.<br />Classification of Evidence: This case series provides Class IV evidence that treatment with olaparib/TMZ may result in radiographic response in patients with glioma.<br /> (© 2022 American Academy of Neurology.)
- Subjects :
- Humans
Adult
Temozolomide therapeutic use
Antineoplastic Agents, Alkylating therapeutic use
Dacarbazine therapeutic use
Retrospective Studies
Prospective Studies
Neoplasm Recurrence, Local drug therapy
Glioma diagnostic imaging
Glioma drug therapy
Astrocytoma drug therapy
Brain Neoplasms diagnostic imaging
Brain Neoplasms drug therapy
Subjects
Details
- Language :
- English
- ISSN :
- 1526-632X
- Volume :
- 99
- Issue :
- 17
- Database :
- MEDLINE
- Journal :
- Neurology
- Publication Type :
- Academic Journal
- Accession number :
- 35948444
- Full Text :
- https://doi.org/10.1212/WNL.0000000000201203